ULTRAPHARM LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +4.2%

  £16,035,000 → £16,705,000

• Cash

  +128.8%

  £1,399,000 → £3,201,000

• Net assets

  +47.7%

  £579,000 → £855,000

• Employees

  -14.7%

  150 → 128

• Operating profit

  -24.4%

  £673,000 → £509,000

• Profit before tax

  -27.8%

  £669,000 → £483,000

• Wages

  +10.7%

  £4,006,000 → £4,433,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Notwithstanding net current liabilities of £1,378,000 as at 28 June 2025 (2024: net current liabilities £3,080,000) the financial statements have been prepared on the going concern basis which the directors consider appropriate for the following reasons. When considering going concern, forecasts have been built on a bottom-up basis and stress tested to prepare an approved budget and strategic plan used as a basis for reviewing going concern. Risks and opportunities have been considered, and severe but plausible downside risks have been assessed. Having reviewed the Group's short and medium-term plans and available financial facilities, the Board has reasonable expectations that the Group, and therefore the Company, has adequate resources to continue to operate for the foreseeable future. In making this assessment, the directors have assumed that the amounts owed to Finsbury Food Group Limited, which as at 28 June 2025 amounted to £4,480,000 (2024: £6,200,000) will not be repayable during the going concern period and the Company has received a support letter from Finsbury Food Group Limited (the "Group") stating that, if required, the Group will assist the company in meetings its liabilities, as they fall due for a period no less than 12 months from the date of signing these financial statements. The directors are comfortable with this support based on the factors described below.”

Group structure

1. ULTRAPHARM LIMITED · parent
   1. Ultraeuropa Sp Zoo 1% · Poland · Bakery products
   2. Lifestyle Healthcare Ltd 0.5% · England and Wales · Bakery products

Significant events

• “The company operates in an environment which is continually changing and as a result the risks it faces will also change over time. The global pandemic presented unprecedented challenges worldwide, the demand profile across our product portfolio underwent rapid change and we had to act decisively and adapt quickly to continue producing food products in a way that kept our colleagues safe, whilst at the same time protecting the long-term sustainability of the business.”
• “In FY25 Ultrapharm Limited remain focused on extending, embedding and sustaining the Operational Brilliance Programme by continuing to make incremental improvements to operations.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.